Compare Repligen Corporation Common Stock (RGEN) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SiTime Corporation — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while SiTime Corporation trades at $519.84 (market cap $17.43B). The key difference: SiTime Corporation is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SiTime Corporation for 18 Days on average.
| RGEN | SITM | |
|---|---|---|
Market Cap | $11.14B | $17.43B |
Volume | 1,259,263 | 549,677 |
Sector | Health | Technology |
52-Week High | $194.57 | $901.60 |
52-Week Low | $102.87 | $252.76 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.02B | $16.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SITM trades at $579.66, up 1.68% today, showing strong momentum after recent earnings beats. The stock faces technical headwinds with bearish moving averages but benefits from unanimous analyst buy ratings and a $751.43 consensus price target. Recent Q2 2026 results showed 126.5% revenue growth to $157.43M and the company's first GAAP profit, driven by AI infrastructure demand and the Renesas acquisition.
The outlook remains positive with accelerating AI-driven growth, though high valuations (P/E 966.1) and negative 2025 net income ($-42.9M) pose risks. Institutional buying and strong Q3 guidance support upside potential, but investors should monitor execution on margin expansion and competitive pressures in the timing solutions market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
